[Diffuse chronic mucocutaneous candidiasis: Effects of antimycotics in vitro].
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D002180:Candidiasis, Oral / Q000188:drug therapy; D002648:Child; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D005260:Female; D005437:Flucytosine / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007153:Immunologic Deficiency Syndromes; D007167:Immunotherapy; D008213:Lymphocyte Activation; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000494:pharmacology; D012871:Skin Diseases / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy
D000935:Antifungal Agents; D009761:Nystatin; D000666:Amphotericin B; D005437:Flucytosine; D005472:Fluorouracil
Diffuse chronische mucocutane Candidosis: Das Verhalten der isolierten Candida gegenüber Antimykotica in vitro